Grants and Contributions:
Title:
Clinical Study of Safety and Immunogenicity of Nasal Poly-ICLC (Hiltonol®) for Prophylaxis of COVID-19 in Healthy Adults
Agreement Number:
-
Agreement Value:
$2,099,792.00
Agreement Date:
Mar 18, 2021 - Mar 31, 2022
Description:
The overall goal of this project is to advance the clinical development of Poly-ICLC (Hiltonol®), a broad-spectrum antiviral drug candidate, as an innovative solution to strengthen medical preparedness against viral threats.
Organization:
National Defence
Location:
Vancouver, British Columbia, CA
Reference Number:
032-2020-2021-Q4-00010
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Type:
For-profit organization
Recipient's Operating Name:
ONCOVIR CANADA INC
Recipient's Legal Name:
ONCOVIR CANADA INC
Program:
Innovation for Defence Excellence and Security Program